Hims & Hers abruptly stopped offering a compounded version of Novo Nordisk’s Wegovy after escalating legal pressure from U.S. federal regulators and threats of enforcement action. The company first announced the product and then reversed course amid warnings that selling an unapproved, compounded copy of a patented GLP‑1 could trigger legal and regulatory consequences. The back-and-forth highlights a growing clash between telehealth startups, compounders and drugmakers over access to high-demand obesity drugs. Regulators are signaling that compounded versions of branded biologics and GLP‑1 peptides will face strict scrutiny; Novo Nordisk has been active in pushing back against unauthorized copies. Compounded drugs are made by pharmacies to meet specific patient needs but remain subject to regulatory limits when they substitute for approved products.